185 related articles for article (PubMed ID: 10414727)
1. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer.
Kamat AM; DeHaven JI; Lamm DL
Urology; 1999 Jul; 54(1):56-61. PubMed ID: 10414727
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of common antibiotics against superficial bladder cancer.
Kamat AM; Lamm DL
Urology; 2004 Mar; 63(3):457-60. PubMed ID: 15028437
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics.
Seay TM; Peretsman SJ; Dixon PS
J Urol; 1996 Feb; 155(2):757-62. PubMed ID: 8558720
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin criteria in antimicrobial prophylaxis and bladder cancer recurrence.
Gurtowska N; Kloskowski T; Drewa T
Med Sci Monit; 2010 Oct; 16(10):RA218-23. PubMed ID: 20885364
[TBL] [Abstract][Full Text] [Related]
5. The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro.
Ebisuno S; Inagaki T; Kohjimoto Y; Ohkawa T
Cancer; 1997 Dec; 80(12):2263-7. PubMed ID: 9404703
[TBL] [Abstract][Full Text] [Related]
6. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer.
Seraphim LA; Perrapato SD; Slocum HK; Rustum YM; Huben RP
J Urol; 1991 Mar; 145(3):613-7. PubMed ID: 1900087
[TBL] [Abstract][Full Text] [Related]
7. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity.
See WA; Xia Q
J Natl Cancer Inst; 1992 Apr; 84(7):510-5. PubMed ID: 1545441
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity.
Mizutani Y; Okada Y; Yoshida O; Fukumoto M; Bonavida B
Cancer; 1997 Mar; 79(6):1180-9. PubMed ID: 9070496
[TBL] [Abstract][Full Text] [Related]
9. Intravesical therapy for superficial bladder cancer.
Baselli EC; Greenberg RE
Oncology (Williston Park); 2000 May; 14(5):719-29; discussion 729-31, 734, 737. PubMed ID: 10853462
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Deb AA; Wilson SS; Rove KO; Kumar B; Koul S; Lim DD; Meacham RB; Koul HK
J Urol; 2011 Dec; 186(6):2426-33. PubMed ID: 22019171
[TBL] [Abstract][Full Text] [Related]
13. Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line.
Aranha O; Wood DP; Sarkar FH
Clin Cancer Res; 2000 Mar; 6(3):891-900. PubMed ID: 10741713
[TBL] [Abstract][Full Text] [Related]
14. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.
Pu YS; Hsieh TS; Cheng AL; Tseng NF; Su IJ; Hsieh CY; Lai MK; Tsai TC
Br J Urol; 1996 Jan; 77(1):76-85. PubMed ID: 8653321
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
Kurth K; Tunn U; Ay R; Schröder FH; Pavone-Macaluso M; Debruyne F; ten Kate F; de Pauw M; Sylvester R
J Urol; 1997 Aug; 158(2):378-84. PubMed ID: 9224307
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder.
Saxena S; Agrawal U; Agarwal A; Murthy NS; Mohanty NK
BJU Int; 2006 Nov; 98(5):1012-7. PubMed ID: 17034604
[TBL] [Abstract][Full Text] [Related]
17. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Soloway MS; Jordan AM; Murphy WM
Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of superficial transitional cell bladder carcinoma. Long-term results of trial comparing transurethral resection alone and adjuvant chemotherapy with Doxorubicin].
Milonas D; Mickevicius J; Mickevicius R; Motiejūnas A; Sukys D; Gudinaviciene I
Medicina (Kaunas); 2002; 38 Suppl 1():79-83. PubMed ID: 12556642
[TBL] [Abstract][Full Text] [Related]
19. The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent.
Long JP; Prout GR; Wong YK; Lin CW
J Urol; 1990 May; 143(5):1053-6. PubMed ID: 2329596
[TBL] [Abstract][Full Text] [Related]
20. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
